You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line.
BioFire has submitted a 39-target test to the US Food and Drug Administration. OpGen also has a test in development.
Following its recent acquisition of Curetis, OpGen has also shifted its focus onto its Unyvero molecular diagnostics platform and bioinformatics operations.
The project, coordinated by Jena University Hospital and expected to run for five years, aims to address resistance mechanisms in Gram-negative pathogens.
The firm had been distributing BGI's SARS-CoV-2 test kit but will stop distributing it effective immediately, OpGen's CEO said.
A partnership with Menarini Silicon Biosystems to market Menarini’s portfolio of COVID-19 related products was among its key quarterly milestones.
The additional €5 million from the European Investment Bank will co-fund R&D across the platforms and product portfolios of Curetis and Ares Genetics.
The firm recently announced a collaboration with Sweden’s Karolinska Institute to test COVID-19 pneumonia patients for bacterial co-infections.
The institute will use Curetis' Unyvero Hospitalized Pneumonia panel on high-risk patients admitted to the ICU for COVID-19 pneumonia.
The company's revenue was largely attributed to its Acuitas AMR Gene Panel and Acuitas Lighthouse informatics platform.